Micafungina Teva (Micafungin Sodium)

Micafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis, and it is indicated for the following conditions:

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal Candida infection in immunocompromised patients.
• Prophylaxis of fungal infections in hematopoietic stem cell transplantation: prevents invasive fungal disease in transplant recipients.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for the synthesis of β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell death, while having minimal effect on human cells that lack this pathway.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient temperature elevation after infusion.
• Nausea: mild gastrointestinal discomfort.
• Headache: occasional mild to moderate pain.
• Elevated liver enzymes: transient increase in ALT or AST.

Serious or Rare Side Effects

• Hepatic failure: rare but potentially life‑threatening liver injury.
• Severe hypersensitivity: including anaphylaxis and angioedema.
• Renal dysfunction: acute kidney injury in susceptible patients.

When using Micafungina Teva, clinicians should observe several safety measures.

• Monitor liver function: check baseline and periodic ALT/AST levels.
• Assess renal function: evaluate serum creatinine before and during therapy.
• Evaluate for hypersensitivity: discontinue if signs of severe allergic reaction appear.
• Use caution in cardiac disease: monitor for hypotension during infusion.
• Adjust in severe hepatic impairment: consider dose modification if needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Cyclosporine: may increase cyclosporine levels, risking nephrotoxicity.
• Rifampin: may lower micafungin concentrations, reducing antifungal effect.
• Tacrolimus: can raise tacrolimus exposure, requiring dose adjustment.

Moderate Interactions (Monitor Closely)

• Fluconazole: potential additive hepatotoxicity; monitor liver enzymes.
• Voriconazole: may increase risk of liver enzyme elevation.
• Warfarin: monitor INR for possible changes in anticoagulant effect.